Degasperi E, Anolli MP, Jachs M, Reiberger T, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
PMID: 39793613